Cargando…

The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy

To assess the potential clinical utility of cell-free DNA (cfDNA)-based biomarkers for identifying gastric cancer (GC) patients who benefit from nivolumab. From 31 GC patients treated with nivolumab monotherapy (240 mg/body, Bi-weekly) in 3rd or later line setting, we prospectively collected blood s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inagaki, Chiaki, Kawakami, Hisato, Maeda, Daichi, Sakai, Daisuke, Urakawa, Shinya, Nishida, Kentaro, Kudo, Toshihiro, Doki, Yuichiro, Eguchi, Hidetoshi, Wada, Hisashi, Satoh, Taroh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079661/ https://www.ncbi.nlm.nih.gov/pubmed/37024664 http://dx.doi.org/10.1038/s41598-023-32645-x

Ejemplares similares

Nivolumab-induced interstitial lung disease in a patient with gastric cancer
por: Kimura, Akie, et al.
Publicado: (2019)

Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: A case report
por: Inagaki, Chiaki, et al.
Publicado: (2019)

A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis
por: Urakawa, Shinya, et al.
Publicado: (2017)

Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer
por: Hagi, Takaomi, et al.
Publicado: (2020)

Computational trans-omics approach characterised methylomic and transcriptomic involvements and identified novel therapeutic targets for chemoresistance in gastrointestinal cancer stem cells
por: Konno, Masamitsu, et al.
Publicado: (2018)

Clinical Utility of Next-Generation Sequencing-Based Panel Testing under the Universal Health-Care System in Japan: A Retrospective Analysis at a Single University Hospital
por: Inagaki, Chiaki, et al.
Publicado: (2021)

Enzymes of the one-carbon folate metabolism as anticancer targets predicted by survival rate analysis
por: Koseki, Jun, et al.
Publicado: (2018)

Targeting the regulation of aberrant protein production pathway in gastrointestinal cancer treatment
por: Sato, Hiromichi, et al.
Publicado: (2022)

Survival impact of microsatellite instability in stage II gastric cancer patients who received S-1 adjuvant monotherapy after curative resection
por: Sato, Chihiro, et al.
Publicado: (2023)

Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)
por: Nishizawa, Yujiro, et al.
Publicado: (2021)

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
por: Matsuda, Chu, et al.
Publicado: (2022)

Comprehensive profiling of novel epithelial–mesenchymal transition mediators and their clinical significance in colorectal cancer
por: Ishikawa, Satoshi, et al.
Publicado: (2021)

Specific activation of glycolytic enzyme enolase 2 in BRAF V600E‐mutated colorectal cancer
por: Yukimoto, Ryohei, et al.
Publicado: (2021)

Clinical outcomes of neoadjuvant chemotherapy for resectable colorectal liver metastasis with intermediate risk of postoperative recurrence: A multi‐institutional retrospective study
por: Noda, Takehiro, et al.
Publicado: (2022)

Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy
por: Yamaguchi, Toshifumi, et al.
Publicado: (2022)

Application of C. elegans cancer screening test for the detection of pancreatic tumor in genetically engineered mice
por: Ueda, Yuji, et al.
Publicado: (2019)

Locally advanced rectal cancer receiving total neoadjuvant therapy combined with nivolumab: a case report and literature review
por: Mori, Ryota, et al.
Publicado: (2022)

Diffuse alveolar hemorrhage with nivolumab monotherapy
por: Shannon, Vickie R., et al.
Publicado: (2020)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Oncogene c-Myc promotes epitranscriptome m(6)A reader YTHDF1 expression in colorectal cancer
por: Nishizawa, Yujiro, et al.
Publicado: (2017)

Endogenous CXCL9 affects prognosis by regulating tumor‐infiltrating natural killer cells in intrahepatic cholangiocarcinoma
por: Fukuda, Yasunari, et al.
Publicado: (2020)

Convolutional Neural Network Can Recognize Drug Resistance of Single Cancer Cells
por: Yanagisawa, Kiminori, et al.
Publicado: (2020)

Liver resection combined with inferior vena cava resection and reconstruction using artificial vascular graft: A literature review
por: Tomimaru, Yoshito, et al.
Publicado: (2018)

Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07)
por: Satoh, Taroh, et al.
Publicado: (2021)

Severe complications of nivolumab monotherapy in an adolescent with malignant melanoma
por: Grzegorczyk, Aleksandra, et al.
Publicado: (2023)

Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer
por: Kato, Ken, et al.
Publicado: (2020)

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
por: Yoshikawa, Akie Kimura, et al.
Publicado: (2022)

Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study
por: Kudo, Toshihiro, et al.
Publicado: (2020)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer
por: Kato, Takeshi, et al.
Publicado: (2023)

Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy
por: Iwasa, Satoru, et al.
Publicado: (2020)

Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)
por: Takahashi, Masanobu, et al.
Publicado: (2020)

Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study
por: Sakai, Daisuke, et al.
Publicado: (2022)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018)

Susceptibility of pancreatic cancer stem cells to reprogramming
por: Noguchi, Kozo, et al.
Publicado: (2015)

Characteristics of early‐onset pancreatic cancer and its association with familial pancreatic cancer and hereditary pancreatic cancer syndromes
por: Eguchi, Hidetoshi, et al.
Publicado: (2020)

Current state of pancreas transplantation in Japan based on the nationwide registry
por: Tomimaru, Yoshito, et al.
Publicado: (2021)

Pancreatic Cancer Research beyond DNA Mutations
por: Sato, Hiromichi, et al.
Publicado: (2022)

Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study
por: Endo, Shunji, et al.
Publicado: (2022)

A resected case of liver metastases from extra-adrenal retroperitoneal paraganglioma with von Recklinghausen’s disease 16 years after the initial surgery
por: Sakai, Kenji, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7qjlns3po66t6g5b0i58jphub1